share_log

Redhill Biopharma | CORRESP: CORRESP

SEC announcement ·  Feb 15 12:59
Summary by Moomoo AI
RedHill Biopharma Ltd., an Israel-based pharmaceutical company, has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-1. The request, filed on February 15, 2024, seeks to advance the effective date to 4:30 p.m. Eastern Time on the same day, or as soon as possible thereafter. This action follows the initial filing of the Registration Statement on February 9, 2024, under file number 333-276979. RedHill Biopharma has designated its counsel, Haynes and Boone, LLP, to receive notification of the Registration Statement's effectiveness via telephone, with a follow-up confirmation in writing.
RedHill Biopharma Ltd., an Israel-based pharmaceutical company, has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-1. The request, filed on February 15, 2024, seeks to advance the effective date to 4:30 p.m. Eastern Time on the same day, or as soon as possible thereafter. This action follows the initial filing of the Registration Statement on February 9, 2024, under file number 333-276979. RedHill Biopharma has designated its counsel, Haynes and Boone, LLP, to receive notification of the Registration Statement's effectiveness via telephone, with a follow-up confirmation in writing.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more